Medicare AdvancePrior AuthHigh impact
Aliqopa™ (copanlisib) (Revised)
Humana·Oncology·Medicare Advantage
We identified it
Jul 22, 2026
Summary
This is a revised Prior Authorization policy for Aliqopa™ (copanlisib) affecting Medicare Advantage members. The policy establishes or modifies authorization requirements for this medication. Specific policy details are unavailable as only a summary was provided, requiring immediate review of the full policy document to understand what changed from the previous version.
Action Required
IMMEDIATELY: Billing and clinical teams must obtain and review the complete policy document at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a586804 to identify specific changes from the prior version. Once details are confirmed: (1) Update billing system with new prior authorization requirements for Aliqopa™; (2) Notify oncology providers of any changed authorization criteria or documentation requirements; (3) Train front desk and billing staff on new submission procedures; (4) Implement the revised policy in practice workflows. Failure to comply will result in claim denials for Aliqopa™ claims submitted without proper authorization per the revised requirements.